83415
document
Naltrexone , an opiate antagonist , fails to modify motor symptoms in patients with Parkinson 's disease . One month of adjunct treatment with naltrexone ( 100 mg/day ) was compared with placebo in a double-blind , randomized , cross-over design in two groups of patients with Parkinson 's disease . The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine . The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia . Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group . These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson 's disease .
83416
Intervention_Pharmacological
Naltrexone
83417
Intervention_Pharmacological
opiate antagonist
83418
Intervention_Pharmacological
naltrexone
83419
Intervention_Control
placebo
83420
Intervention_Pharmacological
bromocriptine
83421
Intervention_Pharmacological
Naltrexone
83422
Intervention_Control
placebo
83423
Outcome_Physical
motor symptoms
83424
Outcome_Physical
motor impairment
83425
Outcome_Physical
motor function
83426
Outcome_Physical
motor impairment
83427
Participant_Condition
patients with Parkinson 's disease .
83428
Participant_Condition
two groups of patients with Parkinson 's disease .
83429
Participant_Sample-size
10
83430
Participant_Condition
patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine